• Mashup Score: 3

    Focus on cardiomyopathy and cardiovascular health of cancer survivors.

    Tweet Tweets with this article
    • Thrilled about our upcoming Scripps Cardiomyopathies and Cardio-Oncology conference this Sep 23 in San Diego! ☀️ Topics will include #amyloid #sarcoid #HCM #geneticCM #cardioonc 🙌🫀 Virtual and in-person. Register here: https://t.co/jyZX5Zkl1k https://t.co/FjJqLqLdfF

  • Mashup Score: 0

    After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

    Tweet Tweets with this article
    • In this @AJMC_Journal interview, Dr Milind Desai at the @ClevelandClinic discusses highlights from the VALOR-HCM trial in patients with advanced symptoms of hypertrophic obstructive #cardiomyopathy (#HCM). Watch here: https://t.co/VTEHZrMTGE https://t.co/fSxgzfXRsh

  • Mashup Score: 0
    Home - 3 month(s) ago

    Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease; however only 1 in 7 patients are diagnosed. Under-recognition of HCM and varied clinical presentation can cause diagnosis delays and misdiagnoses, thereby putting patients at greater risk of cardiovascular events. HCM is no longer a mystery. Evolving guideline recommendations have unlocked the potential for more timely diagnosis and advanced knowledge about pathogenesis has ushered in new and emerging therapeutic strategie

    Tweet Tweets with this article
    • 📝 TEST YOUR SKILLS: Join experts November 11th and learn how to recognize the signs and symptoms associated with #HCM. Crack the case by clicking here: https://t.co/hHLgVe0B4s #CardioTwitter #CardioEd #Cardiologist #MedEd #CMEcredits https://t.co/b4bChvy3q0

  • Mashup Score: 2
    Home - 3 month(s) ago

    Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease; however only 1 in 7 patients are diagnosed. Under-recognition of HCM and varied clinical presentation can cause diagnosis delays and misdiagnoses, thereby putting patients at greater risk of cardiovascular events. HCM is no longer a mystery. Evolving guideline recommendations have unlocked the potential for more timely diagnosis and advanced knowledge about pathogenesis has ushered in new and emerging therapeutic strategie

    Tweet Tweets with this article
    • 📝 TEST YOUR SKILLS: Join experts at #AHA23 November 11th and learn how to recognize the signs and symptoms associated with #HCM. Crack the case by clicking here: https://t.co/JBTacye5WY #CardioTwitter #CardioEd #Cardiologist #MedEd #CMEcredits https://t.co/e3GuJKaMJX